Why the study?
Does DOXO-EMCH allow for higher dosing with reduced toxicity compared to free doxorubicin in patients with solid tumors?
Population
Patients with solid tumors in a Phase I clinical study, and murine tumor models/animals in preclinical…
Comparison
DOXO-EMCH, an albumin-binding prodrug of… vs Free doxorubicin (historical/implied comparison).
Design
Review
Authors
Loading...
May reduce doxorubicin cardiotoxicity; extends preclinical data but leaves clinical adoption open pending larger trials.
Does DOXO-EMCH allow for higher dosing with reduced toxicity compared to free doxorubicin in patients with solid tumors?
DOXO-EMCH is an albumin-binding prodrug of doxorubicin that allows for significantly higher dosing with reduced cardiotoxicity in early clinical and preclinical studies.
Felix Kratz (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: